Bradley J. Monk - Concepedia

Author

Bradley J. Monk

Creighton University ORCID

Also Known As

B J Monk, B MONK, B Monk, B. J. Monk, B. Monk, B.J. MONK, B.J. Monk, BRADLEY J. MONK, Bradley J. Monk, Bradley J Monk

996

Publications

43.8K

Citations

H-Index

137

Concepts

All Affiliations

Creighton University University of Arizona Arizona Oncology University of California, Irvine Medical Center The US Oncology Network

About

Bradley J. Monk is an author at Creighton University specializing in medicine, oncology, and obstetrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	59	182	11.7K
2	Public Health	24	38	1.9K
3	Health Sciences	20	31	2.2K
4	Engineering	1	1	655
5	Social Sciences	1	1	36

Bradley J. Monk

316

Publications

35.5K

Citations

H-Index

Page 1

	Year	Citations
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, New England Journal of Medicine	2016	2.4K
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer Robert A. Burger, Mark F. Brady, Michael A. Bookman, New England Journal of Medicine	2011	2.3K
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix William A. Peters, P.Y. Liu, Rolland J. Barrett, Journal of Clinical Oncology	2000	2.3K
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer Antonio González-Martı́n, Bhavana Pothuri, Ignace Vergote, New England Journal of Medicine	2019	2.1K
Improved Survival with Bevacizumab in Advanced Cervical Cancer Krishnansu S. Tewari, Michael W. Sill, Harry J. Long, New England Journal of Medicine	2014	1.5K
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer Nicoletta Colombo, Coraline Dubot, Domenica Lorusso, New England Journal of Medicine	2021	923
Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study Robert A. Burger, Michael W. Sill, Bradley J. Monk, Journal of Clinical Oncology	2007	878
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer Mansoor Raza Mirza, Dana M. Chase, Brian M. Slomovitz, New England Journal of Medicine	2023	718
Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study Bradley J. Monk, Michael W. Sill, D. Scott McMeekin, Journal of Clinical Oncology	2009	681
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240) Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson, The Lancet Advanced Cervical CancerCervical Cancer ManagementCervical CancerCervical HealthMedicine	2017	656

Page 1